Azilsartan is an angiotensin receptor blocker indicated for the treatment of any stage of hypertension. A review of pharmacology and clinical role of azilsartan monotherapy and azilsartan/chlorthalidone or azilsartan/amlodipine combination therapies for hypertension management was published in the journal Core Evidence. Randomized controlled trials revealed that azilsartan was superior to other sartans, such as valsartan, olmesartan, and candesartan, in terms of 24-hour ambulatory blood pressure monitoring (ABPM) reduction. The beneficial effect of azilsartan was also associated with similar safety profiles. Azilsartan was found to be superior to any angiotensin-converting enzyme inhibitor, including ramipril, in terms of ABPM results, and noninferior to amlodipine with regard to sleep-BP control. The association of azilsartan and chlorthalidone seemed to be superior to other sartans + thiazide combination therapies for both BP lowering and goal achievement. Clinical trials comparing the combination of azilsartan and amlodipine with placebo revealed its superiority in terms of efficacy. Therefore, azilsartan is a safe and effective treatment option for every stage of hypertension, both as monotherapy or in combination with chlorthalidone or amlodipine. Azilsartan is also beneficial in patients with any degree of renal impairment.